Form D To Observe: Cyteir Therapeutics $5.82 million Financing. Donald Corcoran Filed Nov 15 Form D

Health Care Cyteir Therapeutics, Inc. - Donald Corcoran

Cyteir Therapeutics Financing

Cyteir Therapeutics, Inc., Corporation just filed form D for $5.82 million equity financing. The date of first sale was 2015-10-27. Cyteir Therapeutics was able to finance itself with $5.82 million. That is 100.00% of the round of financing. The total private offering amount was $5.82 million. The fundraising form was filed on 2016-11-15. The reason for the financing was: unspecified.

Cyteir Therapeutics is based in Massachusetts. The firm’s business is Other Health Care. The D form was filed by Donald Corcoran President and CEO. The company was incorporated in 2012. The filler’s address is: 763E Concord Avenue, Cambridge, Ma, Massachusetts, 02138. Donald Corcoran is the related person in the form and it has address: C/O Cyteir Therapeutics, Inc., 763E Concord Avenue, Cambridge, Ma, Massachusetts, 02138. Link to Cyteir Therapeutics Filing: 000166224416000003.

Analysis of Cyteir Therapeutics Offering

On average, startups in the Other Health Care sector, sell 68.60% of the total offering size. Cyteir Therapeutics sold 100.00% of the offering. Could this mean that the trust in Cyteir Therapeutics is high? The average financing size for companies in the Other Health Care industry is $1.16 million. The total amount raised is 401.55% bigger than the average for companies in the Other Health Care sector. The minimum investment for this fundraising is set at $0. If you know more about the reasons for the fundraising, please comment below.

What is Form D? What It Is Used For

Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.

Why Fundraising Reporting Is Good For Cyteir Therapeutics Also

The Form D signed by Donald Corcoran might help Cyteir Therapeutics, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment